S 1117
Alternative Names: Pan-IgG protease-Seismic Therapeutics; S-1117Latest Information Update: 21 Mar 2025
At a glance
- Originator Seismic Bio
- Class Enzymes; Immunoglobulin Fc fragments; Recombinant fusion proteins; Recombinant proteins
- Mechanism of Action Immunoglobulin G degraders; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Autoimmune disorders
- Preclinical Idiopathic thrombocytopenic purpura
Most Recent Events
- 09 Mar 2025 Phase-I clinical trials in Autoimmune disorders (In volunteers) in Australia (IV) (NCT06828393)
- 09 Mar 2025 Phase-I clinical trials in Autoimmune disorders (In volunteers) in Australia (SC) (NCT06828393)
- 14 Feb 2025 Seismic Therapeutic plans a phase I trial for Autoimmune disorders (In volunteers) in first half of 2025 (NCT06828393)